June 8, 2021
MSD’s PD-1 inhibitor Keytruda (pembrolizumab) was the best-selling drug in Japan in May, capturing the top slot for the first time in four months, according to a monthly snapshot report released by Encise. Keytruda netted sales of 9.3 billion yen...read more